Study Makes Case for Rethinking Medicare Drug Price Negotiation Timeline
-
Nov 26, 2024
Small-molecule drugs and biologics may produce similar health benefits, but because small molecules tend to be priced lower than biologics, they often represent better value, according to a recent Health Affairs study. And the study authors argued those findings suggest it could be worth revising how the Medicare Drug Price Negotiation Program is set up.
The Inflation Reduction Act of 2022 requires that Medicare negotiate a Maximum Fair Price for selected small-molecule drugs nine years after they were approved by the FDA. Whereas for selected biologics, the negotiated price takes effect after 13 years.
Read more
© 2025 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters